


AXA Framlington Biotech Z Acc GBP

What is the Fund's objective?

The aim of the AXA Framlington Biotech fund (the underlying 'Fund') is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally (meaning at least 80% of its assets) in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company's financial status, the quality of its management, its expected profitability and prospects for growth.

Cumulative Performance



	3m	6m	1yr	3yrs	5yrs
AXA Framlington Biotech Z Acc GBP	+6.4	+7.4	+26.2	+36.3	+29.7
IA Specialist	+0.1	+9.1	+19.0	+48.3	+47.6

Fund Information

Sector	IA Specialist
Asset Class	Equity
Launch Date	02-Nov-2001
Fund Size	£372.9m / \$499.1m (28-Aug-2026)
Fund Manager	Cinney Zhang Mr. Catherine Tennyson Mr. Christopher Eccles

How does FE fundinfo rate this fund?

FE fundinfo Crown Rating	★★★★★
Risk Score	164

Investment Details

Initial Charge	0.00%
Annual Charges	0.75%
Note to charges	Initial Charges: max.;
Minimum Initial Investment	£ 100,000
Minimum Additional Investment	£ 5,000
Dividend Policy	Mar 01, Sep 01 (Final)

Prices


Unit Type	ACC
Mid	664.10(GBX)
Price Date	18 Sep 2026
Yield	0.00

Codes

Citicode	11VD
SEDOL	B784NS1
ISIN	GB00B784NS11

AXA Framlington Biotech Z Acc GBP

Discrete Performance



	0-12m	12m-24m	24m-36m	36m-48m	48m-60m
AXA Framlington Biotech Z Acc GBP	+26.2	-6.8	+15.9	-6.1	+1.3
IA Specialist	+19.0	+14.7	+8.7	+2.9	-3.3

All prices in Pence Sterling (GBX) unless otherwise specified. Price total return performance figures are calculated on a bid price to bid price basis (mid to mid for OEICs) with net income (dividends) reinvested. Performance figures are shown in Pound Sterling (GBP).

Contact Details


Address

AXA Investment
Managers UK
Limited, 22
Bishopsgate, London
EC2N 4BQ, United
Kingdom, l0345
7775511|https://
www.axa-im.co.uk

AXA Framlington Biotech Z Acc GBP

Asset Allocation (28 Aug 2026)


Rank	Asset Classes	%
1	North American Equities	81.51
2	Europe ex UK Equities	9.71
3	UK Equities	3.79
4	Global Emerging Market Equities	2.38
5	Money Market	1.43
6	Asia Pacific ex Japan Equities	1.18



Powered by data from FE fundinfo

Regional Breakdown (28 Aug 2026)


Rank	Regions	%
1	North America	81.51
2	Europe Ex UK	9.71
3	UK	3.79
4	Emerging	2.38
5	Cash	1.43
6	Developed Asia Pacific ex Japan	1.18



Powered by data from FE fundinfo

Sector Breakdown (28 Aug 2026)

Rank	Sectors	%
1	Biotechnology	94.80
2	Pharmaceuticals	3.76
3	Cash	1.43



Powered by data from FE fundinfo

Top Holdings (28 Aug 2026)

Rank	Largest Holdings	%
1	Vertex Pharmaceuticals Inc	7.89
2	Amgen Inc	7.20

AXA Framlington Biotech Z Acc GBP

Rank	Largest Holdings	%
3	Regeneron Pharmaceuticals Inc	6.98
4	Gilead Sciences Inc	6.25
5	Argenx SE	4.98
6	REVOLUTION Medicines Inc	4.21
7	Insmed Inc	3.64
8	United Therapeutics Corp	3.33
9	Ionis Pharmaceuticals Inc	2.58
10	Mirum Pharmaceuticals Inc	2.51